• Media
  • R&D
  • Sustainability
  • Investors
  • Partnering
  • Diabetes care
  • Growth hormone therapy
  • Haemostasis management
  • Hormone replacement therapy
Overview
Diabetes overview
Facts about diabetes overview
Type 1 diabetes
Type 2 diabetes
Gestational diabetes
Glossary
What is diabetes?
Treating diabetes
Manage your diabetes
Manage your diabetes
Manage your diabetes overview
The importance of good blood sugar control
Exercise and diabetes
Medication
Diet
Emotionel well-being
Insulin pens and needles
Insulin pens and needles overview
FlexPen®
NovoPen® 4
NovoPen Echo®
FlexTouch®
NovoPen® 3
NovoPen® 3 Demi
PenMate®
NovoPen® Junior
InnoLet®
NovoTwist®
NovoFine®
NovoFine® Autocover®
Diabetes medicine
Diabetes medicine overview
Insulins (insulin basics)
Non-insulin treatment
Social support
Social support overview
Coping with diabetes
Self-management
Support from family & friends
Medical care and you
Living with diabetes
Patient stories
Patient support sites
Life with diabetes
Life with diabetes overview
Low blood sugar (Hypoglycaemia)
Insulin to fit your life
Healthy tips
Stress, illness and diabetes
Travelling with diabetes
Children with diabetes
For teachers
Overview
Growth hormone therapy overview
Phamaceutical information
What is growth hormone?
Injection devices
Choosing the right device
FlexPro®
NordiFlex®
NordiFlex® PenMate®
NordiPen®
NordiPenMate®
NordiLet®
Needles
NovoFine®
Growth disorders
GHD (Growth hormone deficiency)
GHDA (Growth hormone deficiency in adults)
SGA (Small for gestational age)
Turner syndrome
Noonan syndrome
Skeletal dysplasia
Chronic renal disease
Programmes & support
Interactive tutorial
Patient organisations
Our partnership with Save the Children
Overview
Haemostasis management overview
Haemostasis
What is Haemostasis?
Haemostasis management
Disease areas
Introduction
Congenital haemophilia
Acquired haemophilia
Factor VII Deficiency
Glanzmann's thrombasthenia
Educational
Links
Patient story
Overview
Hormone replacement therapy overview
About HRT
Introduction
Duration of treatment
Oestrogen
Progestogen
Continuous combined HRT
Sequential combined HRT
Low-dose HRT
About the menopause
Introduction
Symptoms & complaints
Hormonal interaction
Hormonal imbalance
Vaginal atrophy
 
Diabetes care

Exclusively for Health Care Professionals. Stay up to date on Novo Nordisk diabetes products: Victoza®, Levemir®, NovoMix®, NovoRapid® and Devices, and read about current diabetes themes, proven therapeutic options, and knowledge resources and tools for you and your patients.

 

Visit NovoMedLink

  • Haemostasis
    management
  • Growth hormone
    therapy
  • Hormone replacement
    therapy
Overview

Overview

Product info

NovoSeven®

270 µg/kg dose

Room temperature stable

8 mg vial

Haemostasis

Management

Blood coagulation

Educational

Key papers

Treatment guidelines

Services & links

WFH patients'
leaflet

Patient story

Disease areas

Congenital haemophilia

Acquired haemophilia

Factor VII deficiency

Glanzmann's
thrombasthenia

Overview

Overview

Indications

GHD (Growth hormone deficiency)

GHDA (Growth hormone deficiency) in adults

SGA (Small for gestational age)

Turner syndrome

Noonan syndrome

Skeletal dysplasia

Chronic renal disease

Pharmaceutical information

Norditropin®

Injection devices

Norditropin® FlexPro®

Norditropin NordiFlex®

NordiFlex PenMate®

NordiPen® with Norditropin® SimpleXx®

NordiPenMate®

Norditropin® NordiLet®

Needles

NovoFine®

Programmes & support

NordiNet® (outcomes registry)

NordiScience® (HCP support)

NordiCare® (Patient support)

Our partnership with Save the Children

Patient testimonials

Testimonials

Overview

Overview

Our products

Introduction

Activelle®

Eviana®

Novofem®

Estrofem®

Vagifem®

Convenience & compliance

Our history in HRT

About HRT

Introduction

Symptoms & complaints

Duration of treatment

Oestrogen

Progestogen

Continuous combined HRT

Sequential combined HRT

Low-dose HRT

Log in to activate the menu and access the information in the three sections above

Register as a new user

  • Haemostasis
    management
  • Growth hormone
    therapy
  • Hormone replacement
    therapy
Overview

Overview

Product info

NovoSeven®

270 µg/kg dose

Room temperature stable

8 mg vial

Haemostasis

Management

Blood coagulation

Educational

Key papers

Treatment guidelines

Services & links

WFH patients'
leaflet

Patient story

Disease areas

Congenital haemophilia

Acquired haemophilia

Factor VII deficiency

Glanzmann's
thrombasthenia

Overview

Overview

Indications

GHD (Growth hormone deficiency)

GHDA (Growth hormone deficiency) in adults

SGA (Small for gestational age)

Turner syndrome

Noonan syndrome

Skeletal dysplasia

Chronic renal disease

Pharmaceutical information

Norditropin®

Injection devices

Norditropin® FlexPro®

Norditropin NordiFlex®

NordiFlex PenMate®

NordiPen® with Norditropin® SimpleXx®

NordiPenMate®

Norditropin® NordiLet®

Needles

NovoFine®

Programmes & support

NordiNet® (outcomes registry)

NordiScience® (HCP support)

NordiCare® (Patient support)

Our partnership with Save the Children

Patient testimonials

Testimonials

Overview

Overview

Our products

Introduction

Activelle®

Eviana®

Novofem®

Estrofem®

Vagifem®

Convenience & compliance

Our history in HRT

About HRT

Introduction

Symptoms & complaints

Duration of treatment

Oestrogen

Progestogen

Continuous combined HRT

Sequential combined HRT

Low-dose HRT

Log out to deactivate menu

Why only for Health Care Professionals

According to applicable law, only Health Care Professionals are allowed to access the product information in this section.

 

Information for patients and relatives

 

If you are a US visitor, please click here

 
Careers
Overview
Available jobs
Working at Novo Nordisk
Moving to Denmark
Working in
Research & Development
Manufacturing
Corporate functions
Marketing & Sales
Programmes
PhDs & PostDocs
MDs
Students & Graduates
Graduates
Trainees (Danish only)
Students
Scholarships
R&D Master
Events
Events calendar
32 globally oriented graduates needed

Do you have a recent master degree, and do you want a successful career in one of the world's leading pharmaceutical companies? If yes, then the Novo Nordisk Graduate Programme is what you are looking for.


Apply before 12 February

 

 
Facts about Novo Nordisk
Policies
Ownership
Figures
History
Our logo
The Novo Nordisk Way
Novo Nordisk Way Essentials
About Novo Nordisk Way
View Novo Nordisk Way Booklet
Management
Board of Directors
Executive Management
Publications & Presentations
Download centre
Changing diabetes®
Changing Diabetes® Programmes
Leadership forums
World tour
Changing Possibilities in Haemophilia®
Our ambitions
HERO
World Heamophilia Day
New domicile
The corporate centre
The architecture
Illustrations
Corporate Governance
Governance model
Shareholder Rights
Novo Nordisk Foundation
General and Shareholder meetings
Board of Directors
Chairmanship and board committees
Audit Committee
Executive Management
Remuneration Principles
Self-assessment
Risk management
Internal control
Assurance
Audit
Recommendations and practices
Novo Nordisk Worldwide
Novo Nordisk in your country
About Novo Nordisk

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries.

Novo Nordisks B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

 
  • Living with diabetes
    • What is diabetes?
    • Keeping well with diabetes
    • Exercise
    • Travelling
    • Patient stories
  • Rate this page
  • Send to a friend
  • Print

 

Back to top
 
  • Accessibility
  • Sitemap
  • Follow us

Who we are

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries.

Novo Nordisk websites

NovoMedLink

Novo Nordisk in the USA
Novo Nordisk in Denmark

Or choose:


Country sites
USA
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Chile
China
Croatia
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hungary
India
Iraq
Ireland
Israel
Italy
Japan
Korea (Republic)
Latvia
Lebanon
Lithuania
Mexico
Netherlands
New Zealand
Norway
Pakistan
Poland
Portugal
Romania
Russian Federation
Serbia
Slovak Republic
Slovenia
South Africa
Spain
Sweden
Switzerland
Syria
Taiwan
Thailand
Turkey
Ukraine
United Kingdom
Venezuela


Other sites
Changing diabetes
NovoMedLink
DAWN study
Hagedorn Research Institute
Diabetes4Patients
Diabetes Barometer
Changing diabetes bus
Media prize
World diabetes day
School challenge
HRT for HCPs
HRT for women
HRT congresses & symposia

Novo Nordisk Worldwide

Addresses and global contacts

Shareholder information

731.50
+3.10
03 February 2012
Stock info

Contact quick links

Customer service and feedback

Comments to our website

Report a concern

Adverse event reporting

Corporate Communication team

  • ® 2011 Novo Nordisk A/S
  • Disclaimer / Privacy